Screening people who are apparently well in order to detect unrecognised disease can be of value to the individuals so diagnosed if early treatment is able to improve their prognosis, and to society at large if their identification leads to primary prevention to protect other people from becoming affected. Screening solely for the benefit of individuals participating in the programme has been termed "prescriptive" screening,1 with the implication that this is something which the doctor prescribes for his patients because it may do them good. But, in considering which programmes should be implemented as health policy, it is not sufficient merely to know that screening does good, one must assess whether it does enough good to outweigh its disadvantages.2 This economic concept of comparing benefits and costs is not new; it was implicit in the first of the 10 precepts of screening listed by Wilson and Jugner3 that the disease should be an important health problem. A few years later Cochrane and Holland were more explicit in their conclusion that, even if screening for porphyria was effective it was not worth while4 as the disease was so rare in the UK.
The severity and frequency of the disease, and the ability of early treatment to improve its prognosis, are not, however, the only aspects to be considered in a full evaluation. The table lists various benefits, setting against each its attendant disadvantages. The first and most important benefit is an improvement in prognosis for some, but not necessarily all, cases detected at screening. Identification of cases already too advanced to benefit from early treatment is certainly no advantage and may do a disservice to these patients by making them aware of their condition for longer, and possibly subjecting them to unpleasant but, in the event, ineffective treatment.
Prescriptive screening
The second benefit is identifying the disease sufficiently early to permit cure by less radical treatment than would be needed if it were allowed to progress to the symptomatic stage. The price paid for this is overtreatment of similar lesions which, if not identified, would not have progressed to overt disease. Trhe third benefit is the saving of resources which may benefit the public sector if the need for expensive services used by late cases can be averted, and the private sector by, for example, extending working capacity. Against this must be set the resource costs of the screening procedure itself, the further investigation of positive cases generated by it, and the overtreatment of non-progressive disease.
The reassurance given by a negative screening result is a rather different benefit in that it applies not to the minority found to be diseased but to the great majority of screened subjects. It is a benefit completely independent of whether or not early detection improves prognosis. In at least one documented case the expressed demand from the public for the reassurance given by screening was enough to maintain a screening service whose other benefits were unproven.5
The last three disadvantages listed in the table arise from the screening test itself which almost inevitably lacks perfect sensitivity and specificity, thus yielding false negative and false positive results. The false negative patients may ignore symptoms because they feel reassured by their negative test result and may feel resentment and anger when the diagnosis is eventually made. The false positive patients are given needless anxiety and may also suffer physical morbidity from the additional diagnostic investigations (eg, biopsy) needed to establish that they are free from disease. Finally, the tests used for screening may not be entirely safe (eg, amniocentesis).
In ideal theoretical circumstances an evaluation of screening would not only measure the frequency of each of these outcomes of the programme but would also weight each one with an appropriate value, expressed in common units, so that if the sum of units in the benefits column exceeded that in the disadvantages column then screening should be implemented. In practice, of course, it is not possible to achieve this counsel of perfection, due partly to practical difficulties in measuring the frequency of some of the more intangible factors, but mainly to the differing weighting values placed upon them by different members of society. Within the last few decades the enormous development of biochemical, biophysical, and histological diagnostic techniques has made possible early diagnosis of a wide range of disorders in adults as well as in children. This, together with an increasing awareness of the potential disadvantages of screening, has stimulated research into the value of screening for specific disorders. In the remainder of this paper evidence is considered which is currently available on the efficacy of screening for various conditions within the context of morbidity patterns in Britain.
Antenatal screening
In addition to the traditional role of antenatal care in promoting fetal and maternal wellbeing, various tests for specific fetal abnormalities are now available. These fall into two main categories: (i) those which allow treatment of the fetus in utero or in the immediate neonatal period, and (ii) those which reveal conditions for which there is no treatment and in which prognosis for the fetus is so poor that termination of pregnancy is offered to the prospective parents.
Examples of successful screening programmes of the first type are screening maternal serum for a rising titre of Rhesus antibodies (which has become less necessary now that primary prevention of Rhesus incompatability can be achieved) and screening for syphilis. 20-25% would survive as handicapped children, but the physical and, in some cases, mental handicap associated with spina bifida is often very severe and causes immense suffering and distress to the affected children and their families; the main benefit of screening is to avoid the birth of these children.
Another difficulty is the lack of specificity of serum AFP levels, which means that 2-3% of unaffected pregnancies are subjected to amniocentesis, which itself may damage 1-3% of normal fetuses;8 moreover, amniotic fluid AFP may also give false positive results in 0 5% of normal pregnancies, leading to mistaken terminations. In high incidence areas, such as the west of Scotland, the balance of benefit of averted spina bifida births to risks of damaging unaffected pregnancies is likely to be in favour of routine screening and may also be cost effective.9 But, in low risk areas, the balance of benefits to risks is less certain.10 One carefully evaluated programme in south Wales-a high Using trained staff to screen at birth the test has a sensitivity of 92% and a specificity of 93% but it probably suffers from a low repeatability between untrained observers.'7 The younger the infant, the greater the apparent prevalence, and it is suggested that over half of the unstable hips identified soon after birth will become normal in three weeks. Therefore postponement of screening to around 6 weeks of age is sometimes recommended, but the risk of subsequent dislocation is much greater in those with unstable joints in the neonatal period.
Confirmation of positive screening findings is by x ray. The efficacy of treatment, whether by plaster immobilisation in an abducted position or by traction and gradual reduction, in preventing the later sequelae of hip disease, has never been tested in a clinical trial but is accepted as being of value. The former treatment method is not without complications, however, leading in some cases to avascular necrosis of the femoral head. The balance of benefits to disadvantages of screening for congenital dislocation of the hip is not proven to be in favour of screening" but, because it has been practised for so long, it may be regarded as unethical to conduct a trial withholding screening from a control group.
SENSORY IMPAIRMENTS
Screening for deafness in infancy is widely applied and probably leads to earlier correction and hence improved communication, but these benefits are very difficult to quantify."9 Similarly, visual screening detects the early signs of squint and, in some cases, facilitates correction by orthoptic exercises rather than surgery and avoids suppression of vision in the affected eye. OTHER 
DISORDERS
General examinations can detect signs of disordered motor development and conditions such as congenital heart disease. The value of presymptomatic detection of these abnormalities is not known. Experimentally, screening may also be carried out for various inherited metabolic diseases, of which cystic fibrosis is the most important. The prevalence of multiple unreported diseases in elderly people is well recognised. It is doubtful, however, whether detection and treatment of diseases such as those mentioned in the section above are of any real value in the elderly, since the aim of health services in this age group is more to improve the quality of life than to extend its duration. Screening to identify conditions affecting the individual's ability to carry on living independently is therefore more relevant, and there are many instances of multiple screening for disorders of locomotion, vision, hearing, nutrition, and so on, often applied by health visitors on a domiciliary basis.33 Measures of the outcome of treatments to alleviate these conditions are less clear cut than incidence and mortality data which are available for evaluation of screening in younger age groups. This, together with non-compliance with the treatments offered, accounts for the fact that, despite its intuitive "caring" appeal, factual evidence of the benefit of screening the elderly is still lacking.
Conclusion
Most of the disorders for which screening can clearly be recommended are in children. The benefits are more obvious in early life, compliance (of parents) is better, and the costs are considerably less, particularly for congenital disorders where a single examination can establish whether or not the subject is affected. This is in contrast to diseases of adult life where, in view of the usual pattern of increasing incidence with increasing age, repeated screening at intervals is needed. Screening infants for phenylketonuria, hypothyroidism, visual and auditory impairments and, probably, congenital dislocation of the hip is of value, and-subject to the parents' decision to participate-the same is true of antenatal screening for Down's syndrome and neural tube defects in high incidence populations. Screening school children for visual, auditory, and dental disease is worth while. Children's screening programmes that have not yet been proved to be of value include those for cystic fibrosis and scoliosis.
Evaluation of screening for chronic diseases in adults has proved more difficult and lengthy than was first supposed, and it can still be clearly recommended only for cervical cancer. Evidence is, however, accumulating that screening for breast cancer, severe hypercholesterolaemia, and possibly hypertension is probably worth while.
Two problems are encountered in implementing almost every population screening programme. The first is to convince the target population that group.bmj.com on June 1, 2017 -Published by http://jech.bmj.com/ Downloaded from screening is relevant and valuable to them, hence increasing compliance both with screening and with subsequent treatment. The second is to decide the management of borderline abnormalities identified by screening. The extent of "overtreatment" can be determined only by a long term follow-up comparing a screened or treated group with a control group. Although sometimes termed secondary prevention, screening, as a strategy for controlling disease, comes a rather poor third after primary prevention-the winner-and effective treatment of established disease-in second place. This is because of the considerable effort, cost, and possible morbidity it entails for society at large and for screened individuals in particular, only a tiny minority of whom will achieve through it an improved prognosis.
